Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CIT | O14578 | 9/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.40 |
| ▸ | PRKACA | P17612 | 2/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.40 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.40 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PRKCB | P05771 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | MARK3 | P27448 | 1/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093707 | 0.81 | MAP2K1 (0.44) | LRRK2AXL | |
| SCHEMBL31541439 | 0.72 | PRKCI (0.50) | CITROCK2ROCK1PRKD3PRKACA | |
| SCHEMBL23021726 | 0.72 | PRKCI (0.50) | CITROCK2ROCK1PRKD3PRKACA | |
| SCHEMBL31541393 | 0.72 | PRKCI (0.50) | CITROCK2ROCK1PRKD3PRKACA | |
| SCHEMBL14895899 | 0.72 | IKBKB (0.49) | CITROCK2ROCK1PRKD3PRKACA | |
| SCHEMBL84365 | 0.71 | PRKCI (0.53) | CITROCK2ROCK1PRKD3PRKACA | |
| SCHEMBL8687438 | 0.69 | CIT (0.59) | CITROCK2ROCK1PRKD3PRKACA | |
| SCHEMBL8688105 | 0.69 | PRKCI (0.55) | CITROCK2ROCK1PRKD3PRKACA | |
| SCHEMBL24492983 | 0.69 | PRKCI (0.50) | CITROCK2ROCK1PRKD3PRKACA | |
| SCHEMBL31541422 | 0.69 | PRKCI (0.55) | CITROCK2ROCK1PRKD3PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153652-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-04-10 | — | — | US | disclosed |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | BERMAN JUDD M (CA) | 2012-01-12 | — | — | US | disclosed |
| US-20110098277-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2011-04-28 | — | — | US | disclosed |
| US-7879872-B2 | comprising (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof; and gentamicin; wherein combination has an fractional inhibitory coconcentration index value of 0.3 against S. aureus 29213 | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| US-7741339-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2010-06-22 | — | — | US | disclosed |
| US-20090221699-A1 | E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide, useful in the treatment bacterial infections. | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-09-03 | — | — | US | disclosed |
| EP-1560584-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2009-01-14 | — | — | EP | disclosed |
| EP-1608377-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARM INC (CA) | 2008-10-01 | — | — | EP | disclosed |
| US-7250424-B2 | E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide, useful in the treatment bacterial infections. | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-07-31 | — | — | US | disclosed |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-06-29 | — | — | US | disclosed |
| US-20060116394-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2006-06-01 | — | — | US | disclosed |
| US-7049310-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-05-23 | — | — | US | disclosed |
| US-20040147580-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221699-A1 | E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide, useful in the treatment bacterial infections. | ACR, NANP, MDN1 | CIT 1415/4885ROCK2 4067/4885ROCK1 3551/4885 |
| US-20060116394-A1 | Fab I inhibitors | SERPINB1, TMBIM6, GDI2 | CIT 1029/4885ROCK2 3804/4885ROCK1 3301/4885 |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | DBI, SERPINB1, CTSF | CIT 1354/4885ROCK2 2173/4885ROCK1 1517/4885 |
| US-20040147580-A1 | Fab I inhibitors | SERPINB1, TMBIM6, GDI1 | CIT 957/4885ROCK2 3723/4885ROCK1 3162/4885 |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | DBI, SERPINB1, CTSF | CIT 1354/4885ROCK2 2173/4885ROCK1 1517/4885 |
| US-20110098277-A1 | Fab I Inhibitors | SERPINB1, TMBIM6, GDI2 | CIT 1029/4885ROCK2 3804/4885ROCK1 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.